The Biden Administration’s decision to reclassify marijuana under the Controlled Substances Act has been cautiously welcomed by state regulators in Massachusetts, as well as cannabis sellers and national advocates. The Drug Enforcement Agency will be moving marijuana from Schedule I, where it is currently listed alongside heroin and LSD, to Schedule III, alongside substances like Tylenol with codeine and anabolic steroids. This change follows the recommendation of the Department of Health and Human Services. According to Ava Callender Concepcion, the acting chair of the Cannabis Control Commission in Massachusetts, this move is a significant step forward for the federal government and has the potential to open up new opportunities for research, medical use, and banking in the regulated cannabis industry that has been established in states like Massachusetts. 

Author